Skip to main content
English
Català
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
2 May 2013
Oryzon to Present its LSD1 programs in Acute Leukemias and in Neurodegenerative disorders at the GTC’s 3rd Epigenetics in Drug Discovery conference in Boston
10 September 2012
ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia
13 June 2012
Oryzon assigns Dr. Xavier Luria as Non-Executive Director of Medical and Regulatory Affairs
25 May 2012
Oryzon nominates specific LSD1 inhibitor as drug candidate to enter preclinical development in Acute leukemia and other hematological cancers
8 May 2012
Oryzon to Present its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston
11 April 2012
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia
19 March 2012
Oryzon to attend BIO-Europe Spring 2012 Conference in Amsterdam
20 February 2012
Oryzon participates in a R&D European consortium in Parkinson’s disease
6 February 2012
Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
26 January 2012
Oryzon to Present at 4th CHI X-Gen Congress, Epigenetics, Targets and Therapies on March 6
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
next ›
last »